Healthcare Industry News: Glaucoma
News Release - May 7, 2020
Sight Sciences Introduces the Next-Generation OMNI(R) Surgical System for Microinvasive Glaucoma SurgeryEnhanced Design Offers Improved Ergonomics and Procedural Efficiency for the Only Device that Targets the Three Points of Resistance in the Conventional Outflow Pathway
MENLO PARK, Calif., May 7, 2020 -- (Healthcare Sales & Marketing Network) -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, Glaucoma and dry eye disease, today announced the launch of its next-generation OMNI® Surgical System for microinvasive Glaucoma surgery (MIGS) procedures.
The OMNI Surgical System combines two distinct angle procedures – ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS device that allows surgeons to target all three points of aqueous humor outflow resistance – trabecular meshwork, Schlemm's canal and distal collector channels.
"We designed the next generation of our OMNI Surgical System to provide improved ergonomics, intuitive use and smooth microcatheter deployment and retraction, while continuing to deliver excellent outcomes as a standalone treatment, or as a procedure performed in conjunction with cataract surgery," said Sight Sciences Chief Commercial Officer, Shawn O'Neil. "We're excited to announce the availability of this improved system, which incorporates many changes based on feedback from our physician customers."
The upgraded system features several updates designed to enhance its ergonomics and usability including:
- An updated Luer lock fitting and pull pin to provide increased efficiency in the priming and preparation of the device,
- An ergonomic handle and flexi-grip surface, which fits comfortably and provides stability in the surgeon's hand, and
- Enhanced gearing and intuitive wheel design that enables seamless deployment and retraction of the microcatheter.
Initial published results from early use of the OMNI Surgical System show meaningful reductions in intraocular pressure (IOP) and medication use.1 Several large-scale, multi-center retrospective and prospective MIGS clinical studies further evaluating the OMNI Surgical System are underway and in their advanced stages.
About OMNI® Surgical System
The OMNI Surgical System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example Healon® or HealonGV® from Abbott Medical Optics (AMO), Amvisc® from Bausch & Lomb, or PROVISC® from Alcon, during ophthalmic surgery. It is also indicated to cut trabecular meshwork tissue during trabeculotomy procedures.
The OMNI System should not be used in cases where there is insufficient visualization of the anterior chamber. The following conditions may prohibit sufficient visualization required for safe and successful cannula and microcatheter placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit surgeon view.
The OMNI Surgical System is a tool, not a treatment, and is indicated for use as specified above; it is not specifically cleared by the FDA to lower intraocular pressure in patients with open angle Glaucoma.
About Sight Sciences
Founded in 2011, Sight Sciences has developed, and is now commercial with intelligently designed and engineered products that target the underlying causes of the world's most prevalent eye diseases. The company's surgical Glaucoma product portfolio features the OMNI® Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target of all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm's canal, and collector channels) with a single device and single corneal incision.
The company's non-surgical Dry Eye product portfolio consists of TearCare® for ophthalmologists and optometrists. TearCare is a software-controlled, wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to facilitate natural meibum expression when meibum is in its softened phase. TearCare's innovative, "equipment-light" product design and the intuitive procedure it facilitates create a highly attractive clinical and economic model for eye care providers.
For more information, please visit sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2020 Sight Sciences. All rights reserved.
Source: Sight Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.